Mirum Pharmaceuticals, Inc.
MIRM
Classement en actions
#3223
Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to... Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia. Furthermore, the company is advancing Volixibat to address intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Founded in 2018, Mirum Pharmaceuticals, Inc. operates from its headquarters in Foster City, California.
Prix de l'action
$85.12
Capitalisation boursière
$5.53B
Changement (1 jour)
3.50%
Changement (1 an)
16.55%
Pays
US
Échange Mirum Pharmaceuticals, Inc. (MIRM)
Catégorie
Healthcare
Ratio P/B pour Mirum Pharmaceuticals, Inc. (MIRM)
Ratio P/B au October 2026 TTM : -486.22
Selon les derniers rapports financiers et le cours de l'action de Mirum Pharmaceuticals, Inc., le ratio cours/valeur comptable actuel (TTM) est -486.22. À la fin de 2023, le ratio P/B était de 4.85.
Historique du ratio P/B pour Mirum Pharmaceuticals, Inc. de 2018 à 2026
Ratio P/B à la fin de chaque année
| Année | Ratio P/B | Changez |
|---|---|---|
| 2026 (TTM) | -486.22 | -5,682.34% |
| 2024 | 8.71 | 79.44% |
| 2023 | 4.85 | -388.93% |
| 2022 | -1.68 | -141.75% |
| 2021 | 4.02 | -258.02% |
| 2020 | -2.55 | -68.43% |
| 2019 | -8.06 | -72.59% |
| 2018 | -29.42 | 0.00% |
Ratio P/B pour des entreprises similaires ou concurrentes
| Entreprise | Ratio P/B | Différence de Ratio P/B | Pays |
|---|---|---|---|
| 6.251 | -101.29% |
US
|
|
| 13.2547 | -102.73% |
US
|
|
| 4.208 | -100.87% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | -101.27% |
NL
|
